The DOI matches its Crossref record.
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Abstract
Depsipeptide (FR901228) is a bicyclic peptide isolated from Chromobacterium violaceum that has demonstrated potent in vitro cytotoxic activity against human tumor cell lines and in vivo efficacy against human tumor xenografts. The primary mechanism of action is through inhibition of histone deacetylase. Initial development was halted due to significant cardiac toxicity. Subsequent studies performed at the National Cancer Institute demonstrated administration without cardiotoxicity was possible by varying the schedule of administration. A phase I trial was designed to determine the maximum tolerated dose and toxicity profile when administered as a 4‐hour infusion weekly × 3 with one week rest. 33 Patients with advanced, incurable cancers were enrolled into this trial and treated with doses of Depsipeptide ranging from 1 mg/m 2 to 17.7 mg/m 2. At doses above 5 mg/m 2, we observed common symptoms of nausea, vomiting, fatigue, and anorexia. Subtle changes in ECGs were seen in several patients. However, no cardiac enzyme abnormalities or reduction in ejection fraction were observed. The MTD was defined as 13.3 mg/m 2 with dose limiting toxicities being grade 3 thrombocytopenia and fatigue. Depsipeptide can be safely administered when given as a 4‐hour infusion and further clinical trials are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Self-citationNovel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Metadata
- Authors
- Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., & Hawkins, M. J.
- Venue
- Journal of Experimental Therapeutics and Oncology
- Publisher
- Wiley
- Published
- 2002-10-22
- Volume
- 2
- Issue
- 6
- Pages
- 325-332
- ISSN
- 1359-4117 (ISSN-L)
- 1533-869X
- OpenAlex
- W1968489542
- Cited by
- 204
- References
- 0
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer. https://app.cochat.ai/papers/10.1046/j.1359-4117.2002.01039.x
- The paper
- Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., & Hawkins, M. J. (2002). A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer. Journal of Experimental Therapeutics and Oncology. https://doi.org/10.1046/j.1359-4117.2002.01039.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.